Clinical Trial

Go-CHOP as the Frontline Therapy for PTCL

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 1, 2023 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05963347
Lead Sponsor Henan Cancer Hospital
Conditions Peripheral T Cell Lymphoma
Enrollment 45 participants
Start Date 2023-08-03
Primary Completion 2025-07-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-01